Intismeran autogene will receive FDA approval by December 31, 2027. Moderna and Merck will push the product toward a biologics license with the FDA Center for Biologics Evaluation and Research, and Merck will be listed as responsible for the BLA filing. The companies will accelerate supply plans ar…